• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Strata Skin Sciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    4/25/25 4:30:45 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email
    false0001051514DE00010515142025-04-252025-04-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934

    April 25, 2025
    Date of Report (Date of earliest event reported)

    graphic

    STRATA SKIN SCIENCES, INC.
    (Exact name of registrant as specified in its charter)

    Delaware
    000-51481
    13-3986004
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Ident. No.)

    5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
     
    19044
    (Address of principal executive offices)
     
    (Zip Code)

    (215) 619-3200
    Registrant’s telephone number, including area code

    N/A
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

    Securities registered pursuant to Section 12(b) of the Act:

     
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which
    registered
     
    Common Stock, $0.001 par value per share
     
    SSKN
      The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 4.01
    Changes in Registrant’s Certifying Accountant.

    On April 23, 2025, Strata Skin Sciences, Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the independent registered accounting firm of the Company. On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum. On April 23, 2025, upon Marcum’s resignation as auditors of the Company and with the approval of the Company’s Audit Committee, CBIZ CPAs P.C. was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025. .

    The reports of Marcum regarding the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

    During the fiscal years ended December 31, 2024 and December 31, 2023, and through April 23, 2025, the date of Marcum’s resignation, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its report and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for the material weakness in the Company’s internal control over financial reporting related to a lack of detailed management review of account reconciliations and account analyses, as reported in the Company’s Annual Reports on Form 10-K for the year ended December 31, 2024.

    During the fiscal years ended December 31, 2024 and December 31, 2023, and through  April 23, 2025, the date of Marcum’s resignation, neither the Company nor anyone on the Company’s behalf consulted with CBIZ CPAs P.C. regarding (i) the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ CPAs P.C. on the Company’s consolidated financial statements, and CBIZ CPAs P.C. did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing, or financial reporting issue or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions), as that term is described in Item 304(a)(1)(iv) of Regulation S-K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

    The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter, dated April 25, 2025, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

    Item 9.01.
    Financial Statements and Exhibits.
     
    (d)
    Exhibits.

     
    16.1
    Letter from  Marcum LLP to the Securities and Exchange Commission dated April 25, 2025 .
     
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    2

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    STRATA SKIN SCIENCES, INC.
         
    Dated:   April 25, 2025
       
         
     
    By:
    /s/John Gillings
     
       
    John Gillings
     
        Chief Accounting Officer


    3

    Get the next $SSKN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Gov Shmuel

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:21:12 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Gillings John T

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:14:28 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:09:40 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

      HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

      6/30/23 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

      HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

      2/14/22 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:57 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:11 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Rafaeli Dolev bought $59,974 worth of shares (19,100 units at $3.14), increasing direct ownership by 15% to 143,156 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:01:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Financials

    Live finance-specific insights

    See more
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

      HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

      3/21/25 1:43:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      11/14/24 2:04:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

      SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      7/18/24 7:42:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      2/14/24 4:51:41 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

      HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, intereste

      5/8/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    SEC Filings

    See more
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      5/14/25 5:25:17 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Strata Skin Sciences Inc.

      10-K/A - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/30/25 4:33:20 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/25/25 4:30:45 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care